225 related articles for article (PubMed ID: 34769200)
21. Promoter methylation of DNA damage repair (DDR) genes in human tumor entities:
Mijnes J; Veeck J; Gaisa NT; Burghardt E; de Ruijter TC; Gostek S; Dahl E; Pfister D; Schmid SC; Knüchel R; Rose M
Clin Epigenetics; 2018; 10():15. PubMed ID: 29445424
[TBL] [Abstract][Full Text] [Related]
22. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
23. DNA Damage Repair Deficiency in Prostate Cancer.
Burdak-Rothkamm S; Mansour WY; Rothkamm K
Trends Cancer; 2020 Nov; 6(11):974-984. PubMed ID: 32517958
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of comprehensive DNA damage repair gene germline mutations in Chinese prostate cancer patients.
Wu J; Wei Y; Pan J; Jin S; Gu W; Gan H; Zhu Y; Ye DW
Int J Cancer; 2021 Feb; 148(3):673-681. PubMed ID: 33006389
[TBL] [Abstract][Full Text] [Related]
25. DNA damage response and prostate cancer: defects, regulation and therapeutic implications.
Karanika S; Karantanos T; Li L; Corn PG; Thompson TC
Oncogene; 2015 May; 34(22):2815-22. PubMed ID: 25132269
[TBL] [Abstract][Full Text] [Related]
26. A comparative study of PCS and PAM50 prostate cancer classification schemes.
Yoon J; Kim M; Posadas EM; Freedland SJ; Liu Y; Davicioni E; Den RB; Trock BJ; Karnes RJ; Klein EA; Freeman MR; You S
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):733-742. PubMed ID: 33531653
[TBL] [Abstract][Full Text] [Related]
27. Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer.
Kim IE; Kim S; Srivastava A; Saraiya B; Mayer T; Kim WJ; Kim IY
BMC Urol; 2019 May; 19(1):33. PubMed ID: 31060606
[TBL] [Abstract][Full Text] [Related]
28. Screening of DNA Damage Repair Genes Involved in the Prognosis of Triple-Negative Breast Cancer Patients Based on Bioinformatics.
Wang N; Gu Y; Chi J; Liu X; Xiong Y; Zhong C; Wang F; Wang X; Li L
Front Genet; 2021; 12():721873. PubMed ID: 34408776
[No Abstract] [Full Text] [Related]
29. DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy.
Ged Y; Chaim JL; DiNatale RG; Knezevic A; Kotecha RR; Carlo MI; Lee CH; Foster A; Feldman DR; Teo MY; Iyer G; Chan T; Patil S; Motzer RJ; Hakimi AA; Voss MH
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32571992
[TBL] [Abstract][Full Text] [Related]
30. DNA Repair in Prostate Cancer: Biology and Clinical Implications.
Mateo J; Boysen G; Barbieri CE; Bryant HE; Castro E; Nelson PS; Olmos D; Pritchard CC; Rubin MA; de Bono JS
Eur Urol; 2017 Mar; 71(3):417-425. PubMed ID: 27590317
[TBL] [Abstract][Full Text] [Related]
31. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer.
Zhao SG; Jackson WC; Kothari V; Schipper MJ; Erho N; Evans JR; Speers C; Hamstra DA; Niknafs YS; Nguyen PL; Schaeffer EM; Ross AE; Den RB; Klein EA; Jenkins RB; Davicioni E; Feng FY
Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):229-36. PubMed ID: 25986914
[TBL] [Abstract][Full Text] [Related]
32. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
Castro E; Romero-Laorden N; Del Pozo A; Lozano R; Medina A; Puente J; Piulats JM; Lorente D; Saez MI; Morales-Barrera R; Gonzalez-Billalabeitia E; Cendón Y; García-Carbonero I; Borrega P; Mendez Vidal MJ; Montesa A; Nombela P; Fernández-Parra E; Gonzalez Del Alba A; Villa-Guzmán JC; Ibáñez K; Rodriguez-Vida A; Magraner-Pardo L; Perez-Valderrama B; Vallespín E; Gallardo E; Vazquez S; Pritchard CC; Lapunzina P; Olmos D
J Clin Oncol; 2019 Feb; 37(6):490-503. PubMed ID: 30625039
[TBL] [Abstract][Full Text] [Related]
33. Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
Fan L; Fei X; Zhu Y; Chi C; Pan J; Sha J; Xin Z; Gong Y; Du X; Wang Y; Dong B; Xue W
J Urol; 2021 Sep; 206(3):630-637. PubMed ID: 33904759
[TBL] [Abstract][Full Text] [Related]
34. Copy Number Amplification of DNA Damage Repair Pathways Potentiates Therapeutic Resistance in Cancer.
Wu Z; Li S; Tang X; Wang Y; Guo W; Cao G; Chen K; Zhang M; Guan M; Yang D
Theranostics; 2020; 10(9):3939-3951. PubMed ID: 32226530
[No Abstract] [Full Text] [Related]
35. Development of an autophagy-related gene expression signature for prognosis prediction in prostate cancer patients.
Hu D; Jiang L; Luo S; Zhao X; Hu H; Zhao G; Tang W
J Transl Med; 2020 Apr; 18(1):160. PubMed ID: 32264916
[TBL] [Abstract][Full Text] [Related]
36. PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.
Ratta R; Guida A; Scotté F; Neuzillet Y; Teillet AB; Lebret T; Beuzeboc P
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):549-560. PubMed ID: 32367009
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer.
Yin M; Grivas P; Wang QE; Mortazavi A; Emamekhoo H; Holder SL; Drabick JJ; Woo MS; Pal S; Vasekar M; Folefac E; Clinton SK; Monk P; Joshi M
Oncologist; 2020 Aug; 25(8):680-688. PubMed ID: 32275806
[TBL] [Abstract][Full Text] [Related]
38. SLCO4C1 promoter methylation is a potential biomarker for prognosis associated with biochemical recurrence-free survival after radical prostatectomy.
Li X; Zhang W; Song J; Zhang X; Ran L; He Y
Clin Epigenetics; 2019 Jul; 11(1):99. PubMed ID: 31288850
[TBL] [Abstract][Full Text] [Related]
39. Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients.
Ankney JA; Xie L; Wrobel JA; Wang L; Chen X
BMC Med Genomics; 2019 May; 12(1):78. PubMed ID: 31146747
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.
Nørgaard M; Haldrup C; Storebjerg TM; Vestergaard EM; Wild PJ; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28930171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
